Research And Markets Research And Markets
0 CHECKOUT

Ovarian Cancer Drug Pipeline Update

  • ID: 1196705
  • August 2016
  • Region: Global
  • Bioseeker
1 of 2

With nearly 60,000 cases of ovarian cancer being diagnosed in the seven major markets each year, this cancer type is by no means small and therefore it remains an important secondary indication for existing and pipeline drugs.

There are today 357 companies plus partners developing 438 drugs targeting ovarian cancer in development. In addition, there are 6 suspended drugs and the accumulated number of ceased drugs over the last years amount to another 124 drugs. Ovarian Cancer Drug Pipeline Update lists all drugs and gives you a progress analysis on each one of them. Identified drugs are linked to 307 different targets. All included targets have been cross-referenced for the presence of mutations associated with human cancer. To date 296 out of the 299 studied drug targets so far have been recorded with somatic mutations. The software application lets you narrow in on these mutations and links out to the mutational analysis for each of the drug targets for detailed information. All drugs targets are further categorized on in the software application by 69 classifications of molecular function and with pathway referrals to BioCarta, KEGG, NCI-Nature and NetPath.

Drug Pipeline Update at a Glance

Investigators
Includes more than 357 principal companies plus their READ MORE >

Note: Product cover images may vary from those shown
2 of 2



Delivery Format: Desktop App plus Online Access to Updates (One Year)

Note: Product cover images may vary from those shown
3 of 2
Note: Product cover images may vary from those shown

RELATED PRODUCTS from Db